Founded by neuroscientist Judith Kelleher-Andersson, NeuroNascent is a privately held biotechnology company developing oral small-molecule therapies designed to stimulate the brain’s own neuron regeneration. Its lead candidate, NNI-362, has completed Phase 1a safety testing in healthy older adults and is being advanced for Alzheimer’s and Parkinson’s disease, while the company’s patented discovery platform also supports programs in other neurological disorders. The Clarksville, Maryland company is led by a team with deep experience in central nervous system drug development.
FDA Orphan Drug Designation for Fragile X Syndrome (NNI-362)
Compliance program
Neuraly IncFounded by drug-delivery researcher Seulki Lee after research with Johns Hopkins scientists, Neuraly is a clinical-stage biotechnology company developing medicines for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Its research centers on glial biology and neuroinflammation, with lead candidate NLY01 advancing through Phase 2 after showing neuroprotective effects in preclinical models. Neuraly operates as a subsidiary of D&D Pharmatech and is guided by scientific co-founders from Johns Hopkins University.GAITHERSBURG, MD
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA